IMMU-27. ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY

BACKGROUND: Pediatric glioblastoma (pGBM), despite being relatively rare (incidence rate: 0.5/100,000), are a leading cause of cancer deaths in children with a median overall survival of 9–15 months. In recent years, immunotherapy has emerged as one of the more promising advances in oncology, with i...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Chandramohan, Vidyalakshmi, Evangelous, Tyler, Lipp, Eric S, Hora, Bhavna, Bigner, Darell D, McLendon, Roger E, Ashley, David M
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2020
Assuntos:
Immunotherapy
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715608/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.381
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares